$MRK: Merck & Co. beats Q3 expectations across metrics and raises full-year

$MRK

$MRK – Merck & Co. beats Q3 expectations across metrics and raises full-year guidance

2026-10-29 10:33:18 UTC · TELEGRAM · All $MRK

?? Positive AI Sentiment (+6.8 / 10)

Q3 Adj. EPS of $2.49 vs. $2.07 consensus; Q3 revenue of $18.09B vs. $17.31B expected.
Keytruda sales reached $8.60B (exp. $8.38B); Gardasil sales $2.00B (exp. $1.75B).
FY Adj. EPS guidance raised to $2.77–$2.82 (from $2.66–$2.76); FY sales midpoint lifted.

Observed market reaction after signal

4h +4.51% · Peak +5.91%